OBJECTIVE: Gallium-68 (Ga-68) DOTA-1-NaI3-octreotide (DOTA-NOC) positron emission tomography (PET)/computed tomography (CT) is increasingly used for neuroendocrine tumors (NETs), often found primarily in the pancreas. However, physiologic uptake of DOTA-NOC has been described in the uncinate process of the pancreas. We studied DOTA-NOC uptake in this organ. MATERIALS AND METHODS: Ninety-six patients underwent 103 DOTA-NOC scans, with pathology-proven pancreatic NET (n = 40) and nonpancreatic NET or biochemical suspicion of NET (n = 63). RESULTS: DOTA-NOC uptake was detected in 35 documented pancreatic tumor sites (SUV: 5.5-165; mean: 25.7 ± 28.8; median: 17.8). Among 63 cases without previous known pathology, uptake was suspicious for tumor in 24 sites (SUV: 4.7-35; mean 16.3 ± 8.0; median: 14.1), and in 38 sites, it was judged as physiological, generally lower relative to adjacent structures (SUV: 2.2-12.6; mean: 6.6 ± 2.2; median: 6.2). In 24 scans with suspected tumor and in 37 of 38 scans with physiological uptake, diagnostic computed tomography or magnetic resonance imaging or endoscopic ultrasonography failed to detect tumor. CONCLUSIONS: Pancreatic DOTA-NOC uptake must be interpreted with caution, and further studies are required.
OBJECTIVE:Gallium-68 (Ga-68) DOTA-1-NaI3-octreotide (DOTA-NOC) positron emission tomography (PET)/computed tomography (CT) is increasingly used for neuroendocrine tumors (NETs), often found primarily in the pancreas. However, physiologic uptake of DOTA-NOC has been described in the uncinate process of the pancreas. We studied DOTA-NOC uptake in this organ. MATERIALS AND METHODS: Ninety-six patients underwent 103 DOTA-NOC scans, with pathology-proven pancreatic NET (n = 40) and nonpancreatic NET or biochemical suspicion of NET (n = 63). RESULTS:DOTA-NOC uptake was detected in 35 documented pancreatic tumor sites (SUV: 5.5-165; mean: 25.7 ± 28.8; median: 17.8). Among 63 cases without previous known pathology, uptake was suspicious for tumor in 24 sites (SUV: 4.7-35; mean 16.3 ± 8.0; median: 14.1), and in 38 sites, it was judged as physiological, generally lower relative to adjacent structures (SUV: 2.2-12.6; mean: 6.6 ± 2.2; median: 6.2). In 24 scans with suspected tumor and in 37 of 38 scans with physiological uptake, diagnostic computed tomography or magnetic resonance imaging or endoscopic ultrasonography failed to detect tumor. CONCLUSIONS:PancreaticDOTA-NOC uptake must be interpreted with caution, and further studies are required.
Authors: L de la Cueva; P Lloro; M J Sangrós; L López Vélez; P Navarro; L Sarria; S Álvarez; D Abós Journal: Clin Transl Oncol Date: 2017-01-31 Impact factor: 3.405
Authors: Ferdinand Seith; Christina Schraml; Gerald Reischl; Konstantin Nikolaou; Christina Pfannenberg; Christian la Fougère; Nina Schwenzer Journal: Radiol Med Date: 2018-06-30 Impact factor: 3.469
Authors: Irene Virgolini; Michael Gabriel; Alexander Kroiss; Elisabeth von Guggenberg; Rupert Prommegger; Boris Warwitz; Bernhard Nilica; Llanos Geraldo Roig; Margarida Rodrigues; Christian Uprimny Journal: Eur J Nucl Med Mol Imaging Date: 2016-05-13 Impact factor: 9.236
Authors: C Schraml; N F Schwenzer; O Sperling; P Aschoff; M P Lichy; M Müller; C Brendle; M K Werner; C D Claussen; C Pfannenberg Journal: Cancer Imaging Date: 2013-03-05 Impact factor: 3.909
Authors: Philippe Thuillier; David Bourhis; Nicolas Karakatsanis; Ulrike Schick; Jean Philippe Metges; Pierre-Yves Salaun; Véronique Kerlan; Ronan Abgral Journal: Medicine (Baltimore) Date: 2020-08-14 Impact factor: 1.817